St. Jude Medical Announces Results From STAR-AF Trial

St. Jude Medical, Inc. (NYSE:STJ) announced the results from the Substrate versus Trigger Ablation for Reduction of Atrial Fibrillation (STAR-AF) trial. The findings were presented during a late-breaking clinical trials session at Heart Rhythm 2009, the annual Heart Rhythm Society’s Scientific Sessions in Boston. The STAR-AF trial, sponsored by St.

More: continued here

Filed under: Cardiovascular on May 18th, 2009